PubRank

Pamela J McLean

Author PubWeight™ 88.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011 6.23
3 Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007 5.49
4 Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 2005 4.71
5 Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem 2004 2.62
6 Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci 2011 2.53
7 Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008 2.35
8 Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008 2.31
9 Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 2012 2.11
10 Retracted SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci 2012 2.00
11 Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 2010 1.90
12 The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 2005 1.85
13 Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A 2006 1.73
14 Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun 2009 1.63
15 Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 2007 1.55
16 Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008 1.45
17 CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem 2008 1.43
18 α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2012 1.42
19 Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther 2009 1.38
20 Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J 2006 1.35
21 Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 2009 1.35
22 Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 2006 1.32
23 Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol Dis 2007 1.22
24 Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One 2011 1.21
25 Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem 2009 1.18
26 Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol 2009 1.15
27 Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol 2012 1.07
28 Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay. J Biol Chem 2011 1.05
29 Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway. J Biol Chem 2006 1.04
30 In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One 2010 1.02
31 Proteotoxicity and cardiac dysfunction. N Engl J Med 2013 1.00
32 Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 2012 1.00
33 Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol 2005 0.98
34 A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem Biophys Res Commun 2004 0.93
35 Dopamine-induced conformational changes in alpha-synuclein. PLoS One 2009 0.93
36 Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 2012 0.91
37 Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol 2014 0.90
38 Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun 2013 0.89
39 Development and screening of contrast agents for in vivo imaging of Parkinson's disease. Mol Imaging Biol 2013 0.87
40 Molecular chaperones and co-chaperones in Parkinson disease. Neuroscientist 2012 0.82
41 Molecular chaperones in Parkinson's disease--present and future. J Parkinsons Dis 2011 0.80
42 Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies. Expert Opin Ther Targets 2015 0.80
43 Studying protein degradation pathways in vivo using a cranial window-based approach. Methods 2010 0.79
44 Drug targets from genetics: α-synuclein. CNS Neurol Disord Drug Targets 2011 0.78
45 Transmission of Soluble and Insoluble α-Synuclein to Mice. J Neuropathol Exp Neurol 2015 0.78